Benefiting from in-depth basic studies on TGF-β in relation to pancreatic, breast, and prostate cancers, drugs targeting TGF-β signaling combined with RT or chemotherapy have reached phase I-II clinical trials 12-15. Here, TGFB1 is linked to prostate carcinoma.